Why the study?
Does catheter-based renal denervation reduce blood pressure and inflammatory markers in patients with resistant hypertension?
Does catheter-based renal denervation reduce blood pressure and inflammatory markers in patients with resistant hypertension?
Renal denervation in resistant hypertension is associated with sustained reductions in ambulatory blood pressure and systemic inflammatory markers like IL-6 and leukocyte count over 12 months.
This retrospective analysis aimed to examine off‐target effects on inflammatory and renal function parameters in n=78 subsequent patients treated with renal denervation ( RDN ) for resistant hypertension. Ambulatory and office blood pressure ( ABP / OBP ), serum creatinine, glomerular filtration rate ( GFR ), cystatin C, C‐reactive protein ( CRP ), interleukin‐6 ( IL ‐6), and white blood cell count ( WBC ) were assessed before, 6 and 12 months after RDN . ABP was significantly reduced by −8.2/−3.8 mm Hg ( P =.002/.021) at 1 year after RDN , while an initial OBP reduction was not sustained during follow‐up. IL ‐6 levels significantly decreased by −0.5 pg/mL ( P =.042) and by −1.7 pg/mL ( P <.001) at 6 and 12 months, baseline IL ‐6 levels possibly predicting ABP response to RDN ( r =−0.295; P =.020). Concurrently, leukocyte count was reduced by −0.5 × 10 3 /μL ( P =.017) and −0.8 × 10 3 /μL ( P <.001), respectively. Serum creatinine and GFR remained unchanged, but we observed a significant increase in cystatin C by 0.04 mg/L ( P =.026) and 0.14 mg/L ( P <.001) at 6 and 12 months after the intervention.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: